If Hairgenetix doesn’t deliver results in 4 months, get a full refund in just 3 simple steps.
Trusted by hundreds and rated
With an 'Excellent' rating of 4.6 stars, based on over 1,200 reviews, our customers' trust in Hairgenetix reflects the remarkable results you can achieve with our hair growth products.
Our products are third-party clinically tested
In a 150-day clinical trial involving 30 men and women aged 18–65 with diverse types of hair loss, the Hairgenetix serum achieved a clinically proven 93% reduction in hair shedding.
Posted by Guilherme Kuceki, Carlos G. Wambier et al. on March 05, 2026
Key Findings at a Glance
A combination treatment of minoxidil, dutasteride, and copper peptides delivered via "tattooing" microneedling produced a median 26.5% hair regrowth across 5 monthly sessions (p < 0.001). The SALT score (a measure of hair loss severity) dropped from a median of 40% to 7.5% — a dramatic improvement. 71.4% of patients (5 out of 7) achieved more than 10% scalp area regrowth. The 5-session protocol was significantly more effective than the previous 3-session protocol (26.5% vs 10%, p = 0.0025). Zero adverse events were reported — no scarring, infection, or complications. These patients had all failed at least 1 year of standard treatment before starting this protocol.
Retrospective clinical study with blinded evaluation + AI assessment
Sample Size
7 male patients, ages 28–55 (median 42)
Primary Outcome
Median 26.5% top scalp area regrowth (IQR: 15.3%–32.8%), p < 0.001
SALT Score Change
Median 40.0% → 7.5% (p < 0.001)
Safety Profile
Zero adverse events — no scarring, infection, or complications
Title
Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators
Authors
Guilherme Kuceki, Austin J. Coppinger, Sara D. Ragi, Luke S. Johnson, Andy Goren, Luiza L. Kalil, Pablo Cirino, Carlos G. Wambier
Journal
JAAD International (Journal of the American Academy of Dermatology)
Year
2025
Study type
Retrospective clinical study with blinded evaluation and AI-assisted assessment
Sample size
7 male patients, ages 28–55, Norwood-Hamilton III–IV
This article is a plain-language summary of a peer-reviewed scientific study. It is intended to make clinical research more accessible and is not medical advice. Always consult a qualified healthcare professional before starting any new treatment. The original study was conducted independently and is not affiliated with Hairgenetix. The MDCT tattooing procedure described in this study is a clinical intervention performed by dermatologists, not a home treatment.
Reviewed by: Esther Bodde — Cosmetic & Medical Doctor (MD)
Why This Research Matters
This 2025 study is one of the first to combine three active ingredients — minoxidil, dutasteride, and copper peptides — delivered directly into the scalp using a medical-grade tattooing technique. What makes it particularly significant is the patient population: all 7 participants had already tried standard hair loss treatments for at least one year without satisfactory results. These were treatment-resistant cases.
The results — a median 26.5% scalp area regrowth with SALT scores dropping from 40% to 7.5% — are among the most dramatic improvements reported in androgenetic alopecia research. The study also pioneered the use of ChatGPT for AI-assisted evaluation of treatment outcomes, finding it aligned within 7.5% of blinded dermatologist assessments.
For copper peptide research specifically, this study demonstrates that delivering copper peptides directly to the follicle (bypassing the skin barrier through microneedling) produces significantly stronger results than topical application alone. This directly validates the biological mechanisms identified in the foundational 2007 Pyo et al. laboratory study and the regenerative pathways reviewed in the 2018 Pickart & Margolina review.
What The Researchers Did
The research team used a technique they call MDCT (Minoxidil-Dutasteride-Copper Peptides Tattooing). Here is what this involved:
The procedure
A compounded solution containing three active ingredients — 0.5% minoxidil (1 mL), 0.1% dutasteride (1 mL), and 1.2% copper peptides (1 mL) — was applied to the scalp. A rotary tattoo machine (Cheyenne, by MT.DERM GmbH) with a 27-needle cartridge was then used to drive the solution into the scalp at 70 Hz oscillation (producing 1,890 perforations per second) with a 2 mm needle exposure depth. The scalp was anaesthetised with lidocaine beforehand.
The protocol
Each patient received 5 monthly sessions of this procedure. Between sessions, patients continued topical minoxidil but did not use oral finasteride, dutasteride, or minoxidil during the study period.
Evaluation method
Results were assessed using three methods: (1) SALT (Severity of Alopecia Tool) scoring, (2) blinded dermatologist evaluation of before/after photographs, and (3) AI-assisted assessment using ChatGPT. The researchers measured TSAR (Top Scalp Area Regrowth) as their primary outcome — the percentage of scalp area that regrew hair.
What Is Retrospective Clinical Analysis?
A retrospective study looks back at patient outcomes after treatment has already been delivered, rather than designing the experiment in advance (which is called a prospective study). The researchers selected patients who had completed the 5-session MDCT protocol and analysed their before-and-after photographs and clinical records.
This design is useful for generating preliminary evidence from real clinical practice, but it has limitations compared to a randomised controlled trial (RCT). There is no control group (patients receiving a placebo), no randomisation, and selection criteria may introduce bias. However, the use of blinded evaluators (dermatologists who didn't know which photos were "before" and "after") and AI-assisted assessment helps reduce subjective bias in the results.
The SALT score used in this study is a standardised tool for measuring alopecia severity. It divides the scalp into four areas and calculates the percentage of hair loss — 0% means full hair, 100% means complete baldness. A drop from 40% to 7.5% represents a major clinical improvement.
What They Found
26.5% median scalp area regrowth (p < 0.001)
The primary outcome — top scalp area regrowth (TSAR) — reached a median of 26.5% (interquartile range: 15.3%–32.8%). This means that more than a quarter of the previously bald scalp area regrew visible hair. The result was highly statistically significant (Wilcoxon signed-rank test, p < 0.001).
SALT score dropped from 40% to 7.5%
The median SALT score decreased from 40.0% (IQR: 23.8%–50.0%) at baseline to 7.5% (IQR: 0%–17.5%) after 5 sessions. In practical terms, patients went from moderate-to-significant hair loss to near-normal hair coverage. A SALT score of 7.5% is barely noticeable.
71.4% of patients achieved clinically meaningful regrowth
Five out of seven patients (71.4%) achieved more than 10% top scalp area regrowth — the study's threshold for clinically meaningful improvement. This is a high response rate, especially considering these patients had already failed standard treatments.
Compared to the same group's earlier 3-session protocol, the 5-session approach produced significantly better outcomes: median TSAR of 26.5% versus 10% with 3 sessions (Mann-Whitney U test, p = 0.0025). This demonstrates a clear dose-response relationship — more sessions produce more regrowth.
Zero adverse events
Despite the invasive nature of the procedure (1,890 needle perforations per second at 2 mm depth), no adverse reactions were reported. No scarring, no infection, no complications across any of the 35 total treatment sessions (7 patients × 5 sessions).
Treatment outcomes from the MDCT copper peptide microneedling protocol. Data from Kuceki et al., JAAD International (2025). PMID: 40225275.
How This Treatment Works: The Biological Mechanisms
The MDCT approach combines three active ingredients with a powerful delivery system, targeting multiple hair loss mechanisms simultaneously:
1. Copper peptides — follicle regeneration and cell protection
As demonstrated in the 2007 Pyo et al. study, copper peptides stimulate dermal papilla cell proliferation and protect them from programmed cell death (caspase-3 reduced 42.7%, PARP reduced 77.5%). The 2018 Pickart & Margolina review showed GHK-Cu affects 31.2% of human genes, boosting collagen synthesis and tissue repair. Delivering these peptides directly to the follicle via microneedling bypasses the skin barrier that limits topical absorption.
2. Minoxidil — direct growth stimulation
Minoxidil is the most widely studied hair growth compound. It works primarily by opening potassium channels in cells, which prolongs the anagen (growth) phase of the hair cycle and increases blood flow to follicles. By delivering it via microneedling rather than topical application, the drug reaches the dermal papilla in higher concentrations.
3. Dutasteride — androgen blocking
Dutasteride is a dual 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT) — the primary hormone responsible for follicle miniaturisation in androgenetic alopecia. By blocking both type I and type II 5-alpha reductase enzymes (compared to finasteride which only blocks type II), dutasteride provides more complete androgen suppression at the follicle level.
The rotary tattoo machine creates 1,890 micro-perforations per second at 2 mm depth, far more uniformly than manual dermarollers. This serves two purposes: it activates wound-healing pathways (Wnt/β-catenin signalling, stem cell activation) that independently stimulate hair growth, and it creates micro-channels that deliver the three active compounds directly to the hair follicle bulge region where stem cells and dermal papilla cells reside.
Clinical Interpretation
This is a combination approach, not copper peptides alone. The 26.5% regrowth cannot be attributed to copper peptides in isolation — minoxidil and dutasteride are also potent active ingredients. However, the addition of copper peptides to the established minoxidil-dutasteride combination represents a meaningful innovation, and the results exceed what minoxidil or dutasteride typically achieve alone.
The treatment-resistant population makes the results more impressive. These patients had all failed at least 1 year of standard treatment. Achieving 26.5% scalp area regrowth in this population suggests the combination addresses mechanisms that monotherapy misses — consistent with the multi-pathway approach of copper peptides.
The SALT score improvement is clinically dramatic. Going from 40% to 7.5% represents a transformation from moderate hair loss to near-normal coverage. In clinical practice, patients typically notice visible improvement at SALT changes of 15-20 percentage points — these patients saw a 32.5 percentage point improvement.
The dose-response between 3 and 5 sessions is encouraging. The jump from 10% to 26.5% regrowth (p = 0.0025) with just 2 additional sessions suggests the biological response continues to accumulate, raising the question of whether 6-8 sessions could produce even greater results.
AI-assisted evaluation is a methodological innovation. Using ChatGPT to independently assess treatment photos (and finding it aligned within 7.5% of dermatologists) demonstrates a scalable approach for future studies. This could enable larger trials with consistent evaluation at lower cost.
How This Compares to Other Research
Dhurat et al. (2013) — The landmark microneedling study showed that microneedling plus minoxidil produced significantly more hair growth than minoxidil alone (mean hair count 91.4 vs 22.2). The Kuceki study builds on this by adding dutasteride and copper peptides and using a tattoo machine for more precise delivery.
Gupta et al. (2022) — This meta-analysis confirmed that microneedling consistently enhances treatment outcomes when combined with topical agents. Kuceki's MDCT protocol takes this a step further with three-agent combination and mechanical tattooing.
Pei et al. (2024) — This meta-analysis of 696 patients showed combination microneedling increased hair density by 13.36–18.11 hairs/cm² and diameter by 2.50 µm. The MDCT results (26.5% TSAR) appear to exceed these pooled outcomes, potentially due to the more intensive tattooing delivery method.
Xu et al. (2024) — This meta-analysis found microneedling plus topicals produced an additional 16 hairs/cm² over topicals alone. Kuceki's approach adds copper peptides and dutasteride to the equation.
Abdi et al. (2023) — This meta-analysis specifically examined minoxidil + microneedling and confirmed the combination's superiority. Kuceki extends this by introducing the copper peptide and dutasteride components.
Topical minoxidil (continued); no oral finasteride, dutasteride, or minoxidil
Patient population
Male, ages 28–55, Norwood-Hamilton III–IV, ≥1 year failed standard treatment
Research Limitations
Very small sample size (n = 7). Seven patients is insufficient to draw definitive conclusions. The results are promising but must be confirmed in larger studies. Statistical significance can be achieved with small samples when effect sizes are large, but generalisability remains uncertain.
No control group. Without a placebo arm or comparison group receiving the procedure without copper peptides, it is impossible to isolate how much of the improvement comes from each individual ingredient versus the combination and delivery method.
Retrospective design. Patients were selected after treatment completion, introducing potential selection bias. A prospective, randomised design would provide stronger evidence.
No objective trichoscopic measurements. The study used visual assessment (SALT scores and photographs) rather than trichoscopic hair density counts. While the SALT tool is standardised, trichoscopic measurements (hairs per cm²) would provide more granular data comparable to other studies.
Cannot separate ingredient contributions. The triple-agent combination means we cannot determine whether copper peptides contributed independently or if results are primarily driven by the minoxidil-dutasteride-microneedling combination. Future studies with individual ingredient arms would clarify this.
Professional procedure only. The tattoo-machine technique requires trained dermatologists and clinical-grade equipment. Results cannot be extrapolated to home microneedling with topical copper peptide serums, which involves less precise delivery at shallower depths.
What This Means For Your Hair
Combination treatment outperforms single agents — this study adds to growing evidence that addressing hair loss through multiple pathways simultaneously produces the strongest results. Copper peptides (cell regeneration), minoxidil (growth stimulation), dutasteride (androgen blocking), and microneedling (enhanced delivery + wound healing) each target different aspects of follicle health.
Treatment-resistant hair loss can still respond — all patients had failed standard treatment for over a year. If you have not seen results from topical minoxidil or other treatments alone, combination approaches may succeed where monotherapy failed.
Delivery method matters as much as ingredients — delivering active compounds directly to the follicle via microneedling is fundamentally more effective than topical application alone. This validates the principle behind combining copper peptide serums with at-home microneedling — though at-home results will be more modest than this clinical-grade tattooing technique.
More sessions produce more results — the significant improvement from 3 sessions (10%) to 5 sessions (26.5%) shows that consistency matters. Whether using professional treatments or home-use copper peptide serums with microneedling, sustained use over months produces cumulative benefits.
Key Terms Explained
SALT Score (Severity of Alopecia Tool)
A standardised tool that measures the percentage of scalp affected by hair loss. 0% = full hair coverage, 100% = complete baldness. The scalp is divided into four areas and scored by visual assessment.
TSAR (Top Scalp Area Regrowth)
The percentage of previously bald scalp area that regrew visible hair during treatment. A TSAR of 26.5% means more than a quarter of the bald area was restored.
Androgenetic alopecia
Pattern baldness — the most common form of hair loss, caused by genetic sensitivity to the hormone dihydrotestosterone (DHT). Classified using the Norwood-Hamilton scale (I–VII in men).
Dutasteride
A dual 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT. More potent than finasteride because it inhibits both type I and type II enzymes.
The specific combination treatment protocol used in this study — three active ingredients delivered via a medical-grade rotary tattoo machine into the scalp.
Norwood-Hamilton Scale
The standard classification system for male pattern baldness, ranging from Type I (minimal recession) to Type VII (extensive loss). Patients in this study were Types III–IV (moderate loss).
Retrospective study
A study design that analyses outcomes after treatment has occurred, by reviewing medical records and photographs. Less rigorous than a prospective randomised trial but useful for generating preliminary evidence.
For more peer-reviewed studies on hair loss and copper peptide therapy, see our full research hub.
Frequently Asked Questions
Can I get this treatment done at home?
No. The MDCT technique uses a clinical-grade rotary tattoo machine operated by a dermatologist, with compounded prescription medications (dutasteride requires a prescription) and scalp anaesthesia. However, the principle of combining copper peptides with microneedling can be applied at home using a dermaroller (0.5–1.5 mm) with a topical copper peptide serum. Results will be more modest than this clinical procedure but still beneficial, as demonstrated in the Dhurat 2013 study showing microneedling + topicals significantly outperforms topicals alone.
Is the 26.5% regrowth due to copper peptides or the other ingredients?
The study cannot separate individual ingredient contributions — all three agents were delivered together. Minoxidil and dutasteride are both proven hair growth treatments, and the microneedling delivery itself activates wound-healing pathways. However, the 2.65× improvement over the 3-session protocol (which used the same ingredients) and the results exceeding typical minoxidil-only or microneedling-only studies suggest the copper peptide component adds meaningful value. The biological basis for this is documented in the 2007 Pyo study and the 2018 Pickart review.
How painful is the tattooing procedure?
The procedure is performed under scalp lidocaine anaesthesia, so patients should not feel significant pain during the treatment. The tattoo machine produces 1,890 perforations per second at 2 mm depth — without anaesthesia this would be quite painful, but lidocaine effectively numbs the treatment area. No patients reported adverse reactions to the procedure.
Why did these patients fail standard treatment before?
All 7 patients had used standard hair loss treatments (topical minoxidil, oral finasteride, or both) for at least one year without satisfactory results. This is common — response rates for topical minoxidil alone are typically 30–40%, meaning 60–70% of patients see limited benefit. The MDCT approach succeeds where standard treatment fails because it delivers higher concentrations directly to the follicle and targets multiple mechanisms simultaneously.
How does this compare to PRP (platelet-rich plasma)?
Both PRP and MDCT are injectable/infusion-based hair treatments. PRP uses the patient's own blood platelets, while MDCT uses a compounded pharmaceutical solution. The 26.5% TSAR in this study compares favourably with PRP studies, which typically report more modest improvements. However, no direct comparison trial exists yet. Both approaches deliver active compounds beneath the skin barrier.
Would more than 5 sessions produce even better results?
The study showed a clear dose-response: 5 sessions produced 26.5% regrowth versus 10% with 3 sessions (p = 0.0025). This suggests that additional sessions may produce further improvement, though the law of diminishing returns likely applies. The authors recommend continued research into optimal treatment duration. The pattern is consistent with the Pei 2024 meta-analysis which found cumulative benefits from repeated microneedling sessions.
Is the ChatGPT evaluation method reliable?
The study found that ChatGPT's visual assessment aligned within 7.5% of blinded dermatologist evaluations — suggesting reasonable reliability for preliminary assessment. However, AI evaluation of clinical photographs is a new methodology not yet standardised in dermatology research. The blinded dermatologist evaluation provides the primary clinical evidence; the AI assessment serves as a supplementary validation.
Are there any long-term safety concerns with scalp tattooing?
No adverse events were reported across 35 total treatment sessions (7 patients × 5 sessions). However, the study follow-up period is limited to the treatment duration. Long-term safety data for repeated scalp tattooing with pharmaceutical compounds is not yet available. The individual components (minoxidil, dutasteride, copper peptides) all have established safety profiles, and the Cheyenne tattoo machine is a medical-grade device designed for precision skin penetration.
Original Study Reference
Kuceki G, Coppinger AJ, Ragi SD, Johnson LS, Goren A, Kalil LL, Cirino P, Wambier CG. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD International. 2025. doi:10.1016/j.jdin.2025.01.012. PMID: 40225275. PMCID: PMC11992372.
How to Cite This Research Summary
Hairgenetix Research Team. "Copper Peptide Microneedling: 26.5% Hair Regrowth in 5 Monthly Sessions (2025 Study)." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-microneedling-hair-regrowth-2025-study
Hairgenetix Research Library — We publish plain-language summaries of peer-reviewed clinical studies on hair growth science. Every article links directly to the original published research. Our goal is to make hair loss science accessible, transparent, and evidence-based. Browse all research summaries →
Advanced Daily Scalp Therapy for Stronger, Healthier Hair
🎯 Designed for hair loss and weak, thinning hair 🔬 Clinically Proven Ingredients 💧 Lightweight, non-greasy for easy daily use
The Hairgenetix Copper Peptide Serum is a powerful daily scalp treatment designed to stimulate hair follicles, reduce shedding, and support long-term hair health[2]. Infused with 10% GHK-Cu and 5% AHK-Cu copper peptides, this advanced formula works at the root level to improve follicle longevity, boost collagen production, and enhance scalp circulation[1]—creating the perfect environment for thicker, healthier hair growth.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu & AHK-Cu Copper Peptides. This professional shampoo, conditioner, and serum set works synergistically to cleanse, nourish, and activate the hair follicles at the root. The shampoo gently removes buildup and prepares the scalp, the conditioner restores moisture and resilience, and the targeted serum delivers concentrated copper peptides directly to the follicle environment.[1] Designed to help reduce shedding, improve hair density[2], and create optimal conditions for healthier, thicker-looking hair with consistent use.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo and conditioner set works synergistically to cleanse, nourish, and strengthen the scalp and hair while supporting follicle regeneration and long-term hair growth.[1] Designed to help reduce shedding, improve hair density[2], and create the optimal environment for healthier, thicker-looking hair with consistent use.
🚀 Stimulates Hair Growth at the Follicle Level 🛡️ Reduces Hair Shedding & Strengthens Roots 🌿 Improves Scalp Health for Thicker, Healthier Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo gently cleanses while supporting scalp regeneration, follicle health, and stronger hair growth.[1] Designed to help reduce shedding, improve hair density[2], and create the optimal environment for healthier, thicker-looking hair with every wash.
Advanced conditioning powered by GHK-Cu copper peptides. This professional conditioner deeply nourishes the hair and scalp while supporting follicle health, strength, and resilience.[1] Designed to reduce breakage, improve hair texture and density[2], and leave hair stronger, smoother, and healthier-looking with every use.
Copper Peptide Microneedling: 26.5% Hair Regrowth in 5 Monthly Sessions (2025 Study)
Research Evidence Summary
Why This Research Matters
This 2025 study is one of the first to combine three active ingredients — minoxidil, dutasteride, and copper peptides — delivered directly into the scalp using a medical-grade tattooing technique. What makes it particularly significant is the patient population: all 7 participants had already tried standard hair loss treatments for at least one year without satisfactory results. These were treatment-resistant cases.
The results — a median 26.5% scalp area regrowth with SALT scores dropping from 40% to 7.5% — are among the most dramatic improvements reported in androgenetic alopecia research. The study also pioneered the use of ChatGPT for AI-assisted evaluation of treatment outcomes, finding it aligned within 7.5% of blinded dermatologist assessments.
For copper peptide research specifically, this study demonstrates that delivering copper peptides directly to the follicle (bypassing the skin barrier through microneedling) produces significantly stronger results than topical application alone. This directly validates the biological mechanisms identified in the foundational 2007 Pyo et al. laboratory study and the regenerative pathways reviewed in the 2018 Pickart & Margolina review.
What The Researchers Did
The research team used a technique they call MDCT (Minoxidil-Dutasteride-Copper Peptides Tattooing). Here is what this involved:
The procedure
A compounded solution containing three active ingredients — 0.5% minoxidil (1 mL), 0.1% dutasteride (1 mL), and 1.2% copper peptides (1 mL) — was applied to the scalp. A rotary tattoo machine (Cheyenne, by MT.DERM GmbH) with a 27-needle cartridge was then used to drive the solution into the scalp at 70 Hz oscillation (producing 1,890 perforations per second) with a 2 mm needle exposure depth. The scalp was anaesthetised with lidocaine beforehand.
The protocol
Each patient received 5 monthly sessions of this procedure. Between sessions, patients continued topical minoxidil but did not use oral finasteride, dutasteride, or minoxidil during the study period.
Evaluation method
Results were assessed using three methods: (1) SALT (Severity of Alopecia Tool) scoring, (2) blinded dermatologist evaluation of before/after photographs, and (3) AI-assisted assessment using ChatGPT. The researchers measured TSAR (Top Scalp Area Regrowth) as their primary outcome — the percentage of scalp area that regrew hair.
What Is Retrospective Clinical Analysis?
A retrospective study looks back at patient outcomes after treatment has already been delivered, rather than designing the experiment in advance (which is called a prospective study). The researchers selected patients who had completed the 5-session MDCT protocol and analysed their before-and-after photographs and clinical records.
This design is useful for generating preliminary evidence from real clinical practice, but it has limitations compared to a randomised controlled trial (RCT). There is no control group (patients receiving a placebo), no randomisation, and selection criteria may introduce bias. However, the use of blinded evaluators (dermatologists who didn't know which photos were "before" and "after") and AI-assisted assessment helps reduce subjective bias in the results.
The SALT score used in this study is a standardised tool for measuring alopecia severity. It divides the scalp into four areas and calculates the percentage of hair loss — 0% means full hair, 100% means complete baldness. A drop from 40% to 7.5% represents a major clinical improvement.
What They Found
The primary outcome — top scalp area regrowth (TSAR) — reached a median of 26.5% (interquartile range: 15.3%–32.8%). This means that more than a quarter of the previously bald scalp area regrew visible hair. The result was highly statistically significant (Wilcoxon signed-rank test, p < 0.001).
The median SALT score decreased from 40.0% (IQR: 23.8%–50.0%) at baseline to 7.5% (IQR: 0%–17.5%) after 5 sessions. In practical terms, patients went from moderate-to-significant hair loss to near-normal hair coverage. A SALT score of 7.5% is barely noticeable.
Five out of seven patients (71.4%) achieved more than 10% top scalp area regrowth — the study's threshold for clinically meaningful improvement. This is a high response rate, especially considering these patients had already failed standard treatments.
Compared to the same group's earlier 3-session protocol, the 5-session approach produced significantly better outcomes: median TSAR of 26.5% versus 10% with 3 sessions (Mann-Whitney U test, p = 0.0025). This demonstrates a clear dose-response relationship — more sessions produce more regrowth.
Despite the invasive nature of the procedure (1,890 needle perforations per second at 2 mm depth), no adverse reactions were reported. No scarring, no infection, no complications across any of the 35 total treatment sessions (7 patients × 5 sessions).
How This Treatment Works: The Biological Mechanisms
The MDCT approach combines three active ingredients with a powerful delivery system, targeting multiple hair loss mechanisms simultaneously:
1. Copper peptides — follicle regeneration and cell protection
As demonstrated in the 2007 Pyo et al. study, copper peptides stimulate dermal papilla cell proliferation and protect them from programmed cell death (caspase-3 reduced 42.7%, PARP reduced 77.5%). The 2018 Pickart & Margolina review showed GHK-Cu affects 31.2% of human genes, boosting collagen synthesis and tissue repair. Delivering these peptides directly to the follicle via microneedling bypasses the skin barrier that limits topical absorption.
2. Minoxidil — direct growth stimulation
Minoxidil is the most widely studied hair growth compound. It works primarily by opening potassium channels in cells, which prolongs the anagen (growth) phase of the hair cycle and increases blood flow to follicles. By delivering it via microneedling rather than topical application, the drug reaches the dermal papilla in higher concentrations.
3. Dutasteride — androgen blocking
Dutasteride is a dual 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT) — the primary hormone responsible for follicle miniaturisation in androgenetic alopecia. By blocking both type I and type II 5-alpha reductase enzymes (compared to finasteride which only blocks type II), dutasteride provides more complete androgen suppression at the follicle level.
4. Tattoo-machine microneedling — enhanced delivery
The rotary tattoo machine creates 1,890 micro-perforations per second at 2 mm depth, far more uniformly than manual dermarollers. This serves two purposes: it activates wound-healing pathways (Wnt/β-catenin signalling, stem cell activation) that independently stimulate hair growth, and it creates micro-channels that deliver the three active compounds directly to the hair follicle bulge region where stem cells and dermal papilla cells reside.
Clinical Interpretation
How This Compares to Other Research
Treatment Protocol
Research Limitations
What This Means For Your Hair
Key Terms Explained
Further Reading
For more peer-reviewed studies on hair loss and copper peptide therapy, see our full research hub.
Frequently Asked Questions
Can I get this treatment done at home?
No. The MDCT technique uses a clinical-grade rotary tattoo machine operated by a dermatologist, with compounded prescription medications (dutasteride requires a prescription) and scalp anaesthesia. However, the principle of combining copper peptides with microneedling can be applied at home using a dermaroller (0.5–1.5 mm) with a topical copper peptide serum. Results will be more modest than this clinical procedure but still beneficial, as demonstrated in the Dhurat 2013 study showing microneedling + topicals significantly outperforms topicals alone.
Is the 26.5% regrowth due to copper peptides or the other ingredients?
The study cannot separate individual ingredient contributions — all three agents were delivered together. Minoxidil and dutasteride are both proven hair growth treatments, and the microneedling delivery itself activates wound-healing pathways. However, the 2.65× improvement over the 3-session protocol (which used the same ingredients) and the results exceeding typical minoxidil-only or microneedling-only studies suggest the copper peptide component adds meaningful value. The biological basis for this is documented in the 2007 Pyo study and the 2018 Pickart review.
How painful is the tattooing procedure?
The procedure is performed under scalp lidocaine anaesthesia, so patients should not feel significant pain during the treatment. The tattoo machine produces 1,890 perforations per second at 2 mm depth — without anaesthesia this would be quite painful, but lidocaine effectively numbs the treatment area. No patients reported adverse reactions to the procedure.
Why did these patients fail standard treatment before?
All 7 patients had used standard hair loss treatments (topical minoxidil, oral finasteride, or both) for at least one year without satisfactory results. This is common — response rates for topical minoxidil alone are typically 30–40%, meaning 60–70% of patients see limited benefit. The MDCT approach succeeds where standard treatment fails because it delivers higher concentrations directly to the follicle and targets multiple mechanisms simultaneously.
How does this compare to PRP (platelet-rich plasma)?
Both PRP and MDCT are injectable/infusion-based hair treatments. PRP uses the patient's own blood platelets, while MDCT uses a compounded pharmaceutical solution. The 26.5% TSAR in this study compares favourably with PRP studies, which typically report more modest improvements. However, no direct comparison trial exists yet. Both approaches deliver active compounds beneath the skin barrier.
Would more than 5 sessions produce even better results?
The study showed a clear dose-response: 5 sessions produced 26.5% regrowth versus 10% with 3 sessions (p = 0.0025). This suggests that additional sessions may produce further improvement, though the law of diminishing returns likely applies. The authors recommend continued research into optimal treatment duration. The pattern is consistent with the Pei 2024 meta-analysis which found cumulative benefits from repeated microneedling sessions.
Is the ChatGPT evaluation method reliable?
The study found that ChatGPT's visual assessment aligned within 7.5% of blinded dermatologist evaluations — suggesting reasonable reliability for preliminary assessment. However, AI evaluation of clinical photographs is a new methodology not yet standardised in dermatology research. The blinded dermatologist evaluation provides the primary clinical evidence; the AI assessment serves as a supplementary validation.
Are there any long-term safety concerns with scalp tattooing?
No adverse events were reported across 35 total treatment sessions (7 patients × 5 sessions). However, the study follow-up period is limited to the treatment duration. Long-term safety data for repeated scalp tattooing with pharmaceutical compounds is not yet available. The individual components (minoxidil, dutasteride, copper peptides) all have established safety profiles, and the Cheyenne tattoo machine is a medical-grade device designed for precision skin penetration.
How to Cite This Research Summary
Hairgenetix Research Team. "Copper Peptide Microneedling: 26.5% Hair Regrowth in 5 Monthly Sessions (2025 Study)." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-microneedling-hair-regrowth-2025-study
Related Research on Hairgenetix